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Abstract
Objectives. To investigate the frequency and predictors of sustained 28-joint DAS (DAS28) remission and low disease
activity (LDA) in patients receiving anti-TNF therapy and changes in responses over a 12 year period.
Methods. Data from the British Society for Rheumatology Biologics Registry for Rheumatoid Arthritis were used.
Sustained remission and LDA were defined according to DAS28-ESR thresholds sustained for 6 months. The dataset
was dichotomized into sequential chronological subgroups (20012010 and 20102013). Predictive variables were iden-
tified from a previous systematic review and modelled using multivariable logistic regression.
Results. Overall, 2144 (14.9%) and 3802 (26.3%) patients achieved sustained remission or LDA, respectively. Positive
predictors of sustained remission/LDA included adalimumab (vs etanercept), greater patient global assessment, never-
and ex-smoker status (vs current smoking), greater swollen joint count, more recent commencement of anti-TNF and
MTX co-prescription (except in the 20102013 subgroup). Negative predictors of sustained remission and LDA included
poor baseline functional status (HAQ), female gender, older age at starting anti-TNF, infliximab use (vs etanercept),
increasing BMI and greater baseline ESR. Increasing tender joint count was negatively associated with sustained LDA
only. The overall proportion of patients achieving sustained remission and LDA has increased significantly over time.
Conclusion. Sustained remission/LDA on anti-TNF treatment remains uncommon. Adalimumab use, greater patient
global assessment, never- and ex-smoker status, greater swollen joint count, more recent commencement of anti-TNF
and MTX co-prescription are associated with achievement of sustained remission/LDA. However, co-prescription of MTX
was not associated with an increased likelihood of achieving sustained remission or LDA in the analysis of more recent
anti-TNF responses.
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Rheumatology key messages
. The demographics of rheumatoid arthritis patients commencing their first anti-TNF has changed significantly since
2001.
. Sustained remission in anti-TNF-treated rheumatoid arthritis patients has increased significantly since 2001.
. Clinical predictors are associated with sustained DAS28 remission in anti-TNF-treated rheumatoid arthritis
patients.
Introduction
Treat-to-target strategies and increased use of biologic
agents over the past decade have improved outcomes
for patients with RA [1, 2]. Initial use of biologic therapies
included patients with long-standing severe disease re-
fractory to conventional synthetic DMARD (csDMARD)
therapy. Increasing biologic treatment availability and rec-
ognition of the value of treat-to-target strategies have
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seen them placed earlier in the RA treatment paradigm for
patients not responding adequately to csDMARDs [3].
Extensive clinical trial and registry data support the effi-
cacy of anti-TNF biologic drugs [4, 5], although most stu-
dies report outcomes at only a single time point. Studies
of sustained response to anti-TNF are sparse and evi-
dence suggesting how often and in which patients sus-
tained remission occurs is lacking. Several factors have
been identified as being associated with sustained remis-
sion in individuals taking both csDMARDs and anti-TNFs
[6, 7], although relatively few studies have investigated
this outcome. While sustained remission is desirable,
low disease activity (LDA) may be an acceptable and
more realistic target. Therefore, understanding predictors
of sustained LDA is also important.
Anti-TNFs form a routine part of clinical care for patients
with RA. Understanding how often and in whom sustained
remission/LDA occurs is essential to appreciate the likely
success of treatment. With increasing availability and ear-
lier initiation of anti-TNFs and other biologics, it is possible
that both the frequency of sustained remission/LDA and
predictors associated with these outcomes may have
changed over time.
This study investigates the frequency of sustained re-
mission and LDA in patients receiving anti-TNF therapy,
the predictors associated with achieving these outcomes
and how these predictors and the frequency of these out-
comes may have changed over 12 years.
Methods
The British Society for Rheumatology Biologics Registry
for Rheumatoid Arthritis (BSRBR-RA) is a national, pro-
spective, longitudinal, observational study examining the
long-term safety of biologic agents in patients with RA in
the UK. Ethical approval was obtained from the
Multicentre Research Ethics Committee for the North-
West of England. All patients enrolled provided written
informed consent. The methods of the BSRBR-RA have
been described previously [8].
Biologics use in England and Wales is directed by
National Institute for Health and Care Excellence guidance
[9], which requires patients to have persistent high dis-
ease activity [a 28-joint DAS (DAS28) score >5.1 on two
occasions, 1 month apart] despite treatment with at least
two csDMARDs, one of which should be MTX (unless
contraindicated). Therefore the BSRBR-RA is a cohort en-
riched for high baseline disease activity.
Remission and LDA were defined according to DAS28-
ESR thresholds (remission <2.6, LDA 2.6<3.2). The
BSRBR-RA collects DAS28 outcomes on a 6 month
basis for the first 3 years. Thereafter, data collection is
performed annually. Sustained remission or LDA was
defined as any patient achieving the required DAS28-
ESR thresholds on two sequential follow-ups during the
first 3 years of data collection. Only one period of sus-
tained remission/LDA was counted per individual and
analysis included only individuals starting on an anti-TNF
as their first biologic agent. Point remission was defined
as any patients who had one or more recorded
occurrences of non-consecutive episodes of remission.
Patient data were censored at the time of switching to
another anti-TNF or biologic agent or discontinuation of
anti-TNF treatment. Possible clinical and demographic
variables associated with response were identified from
a systematic review [7] and associations were examined
using a generalized linear model, specifically, logistic re-
gression, as the response examined (sustained remission/
not sustained remission or LDA/not LDA) was binary.
To examine changes in prescribing and patient charac-
teristics over time, the dataset was split into two chrono-
logical subgroups (20012010 and 20102013).
Recruitment for anti-TNF medications (etanercept, inflixi-
mab and adalimumab) to the BSRBR-RA was paused
from 2007 until 2010 and then restarted in 2010 to include
etanercept, infliximab, adalimumab and certolizumab (the
recruitment of which was targeted). These factors made
2010 an appropriate time point to split the cohort. Only
individuals enrolled up to 2013 were included in the ana-
lyses to allow for three complete years of data collection
(up to a data censor date of 30 September 2016).
Data were examined to ensure ‘missingness’ occurred
at random and bootstrapped multiple imputation was
used for missing data. Differences between subgroup
baseline characteristics and comparisons of frequency
of remission and LDA rates were examined using unpaired
t-tests and 2. Univariable regression analysis (using a
threshold P-value of 0.05) confirmed variables for inclu-
sion in the final multivariable logistic regression model.
Binary vector multiplication identified individuals in sus-
tained remission/LDA. Uni- and multivariable regression
modelling was performed on all imputed datasets [using
the generalized linear model package in R (R Foundation
for Statistical Computing, Vienna, Austria)] and results
combined using Ruben’s rules [10].
Results
Changing patient demographics
A total of 14 436 patients with RA starting their first anti-
TNF were enrolled between 2001 and 2013. Of these,
13 115 patients were recruited between 2001 and 2010
and 1321 between 2010 and 2013. Due to the BSRBR-
RA study design, anti-TNF use was split equally between
etanercept, infliximab and adalimumab for the 20012010
subgroup. Recruitment targets changed in 2010 and cer-
tolizumab was added to the register. In the 20102013
subgroup, 659 patients (49.9%) were taking certolizumab,
compared with 376 (28.5%), 260 (21.0%) and 26 (2.0%)
patients taking etanercept, adalimumab and infliximab,
respectively. Baseline MTX use increased over time from
55.9% (7332 patients, 20012010 subgroup) to 63.9%
(844 patients, 20102013 subgroup) (Table 1).
The mean age, patient global assessment (PGA; mea-
sured by visual analogue scale in millimetres) and gender
composition at commencement of anti-TNF did not
change over time. The median number of swollen joints
decreased by nearly three swollen joints, although the
number of tender joints only decreased by one. The
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mean DAS28-ESR, baseline disability (measured by the
HAQ), ESR and disease duration (defined as the year of
onset of symptoms to the year of commencing anti-TNF)
also decreased (P< 0.01; Table 1).
BMI in the 20102013 subgroup was significantly
greater than in the 20012010 subgroup. There was a
declining trend in current and ex-smokers, with an
increasing proportion of never smokers (40.2% to
44.1%, P< 0.01). The time from when a patient first saw
a rheumatologist to commencement of anti-TNF
decreased from a median of 10 to 6 years (P< 0.01;
Table 1).
Achievement of sustained remission and LDA
A total of 2144 (14.9%) patients achieved one or more
episodes of sustained remission in the whole cohort
(Table 2). Point remission was more common [3175 pa-
tients (22.0%) in the whole cohort], but still infrequent. The
proportion of patients achieving point remission increased
between 20012010 and 20102013 (21.4% vs 29.6%,
P< 0.001; Table 2).
Sustained LDA (or better) was also infrequent, with 3802
patients (26.3%) identified in the whole cohort. Of these,
2144 patients (56.4%) were also in sustained remission.
Furthermore, the proportion of patients achieving sus-
tained LDA who were also in sustained remission
increased from 55.6% (1875 patients, 20012010 sub-
group) to 66.7% (285 patients, 20102013 subgroup;
P< 0.001).
A large number of patients [1031 (27.1%)] achieving
sustained LDA across the whole cohort also had at least
one episode of point remission. Indeed, only 627 (16.5%)
patients who achieved sustained LDA had no recorded
episodes of remission (Table 2).
The proportion of sustained LDA patients achieving at
least one episode of point remission has remained stable
over time. However, the proportion of patients who never
achieved remission in the sustained LDA group decreased
from 4.4% in the 20012010 subgroup to 2.7% in the
20102013 subgroup, although the numbers are small
(Table 2).
Predictors of sustained remission
Univariable analysis (inclusion threshold P< 0.05) con-
firmed the inclusion of all variables in the multivariable
model except smoking. However, given the evidence of
a link between smoking and RA pathogenesis and severity
[11, 12], smoking data were included in the multivariable
regression model.
Adalimumab (vs etanercept), baseline MTX, greater
PGA and ex-smoker status (vs current smoker) were asso-
ciated with an increased likelihood of sustained remission
in the whole cohort and the 20012010 subgroup. Never-
smoker status, greater swollen joint count (SJC) and more
recent commencement of anti-TNF were also associated
with an improved likelihood of achieving sustained remis-
sion in the 20012010 subgroup but not the whole cohort.
Female gender, older age at starting anti-TNF, infliximab
use (vs etanercept), increasing BMI and greater baseline
TABLE 1 Change in patient characteristics at the start of the first anti-TNF recorded in the BSRBR-RA over time
Variable
Whole cohort
(20012013)
20012010
subgroup
20102013
subgroup
P-valuesa
(comparing
subgroups)
Patients, n 14 436 13 115 1321 NA
Female, % 76.3 76.3 75.7 0.6
Age, mean (S.D.), years 56.0 (12.3) 56.0 (12.2) 56.3 (12.7) 0.4
DAS28-ESR (range 010), mean (S.D.) 6.5 (1.0) 6.6 (1.0) 6.0 (1.0) <0.01
Swollen joint count (range 028), mean (S.D.) 11.1 (6.2) 11.4 (6.2) 8.7 (5.2) <0.01
Tender joint count (range 028), mean (S.D.) 15.5 (7.4) 15.6 (7.4) 14.6 (7.5) <0.01
Patient global assessment (range 0100 mm), mean (S.D.) 72.5 (19.8) 72.5 (19.8) 72.2 (19.5) 0.6
ESR (mm/h), mean (S.D.) 44.7(28.2) 46.0 (28.3) 29.6 (22.8) <0.01
HAQ (range 03), mean (S.D.) 2.0 (0.6) 2.0 (0.6) 1.6 (0.7) <0.01
BMI (kg/m2), mean (S.D.) 27.2 (8.1) 27.0 (6.8) 29.6 (17.1) <0.01
Disease duration (years), mean, median (S.D.) 12.7, 11.0 (9.6) 13.0, 11.0 (9.6) 9.6, 6.0 (9.5) <0.01
Time from first rheumatology consult to biologics (years),
mean, median (S.D.)
12.0, 10.0 (9.0) 12.2, 10.0 (8.9) 9.5, 6.0 (9.0) <0.01
Baseline MTX, n (%) 8176 (56.6%) 7332 (55.9%) 844 (63.9%) <0.01
Etanercept, n (%) 4852 (33.6) 4449 (33.9) 376 (28.5) NA
Infliximab, n (%) 4222 (29.2) 4196 (32.0) 26 (2.0) NA
Certolizumab, n (%) 659 (4.6) 0.0 659 (49.9) NA
Adalimumab, n (%) 4730 (32.8) 4471 (34.1) 260 (21.0) NA
Current smokers, n (%) 3108 (21.8) 2861 (22.0) 247 (19.9) 0.03
Ever smoker, n (%) 5368 (37.7) 4922 (37.8) 446 (36.0)
Never smoker, n (%) 5778 (40.5) 5232 (40.2) 546 (44.1)
aUsing unpaired t-test except gender and smoking data, which used 2.
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ESR were all negatively associated with the likelihood of
achieving sustained remission in the cohort as a whole
and the 20012010 subgroup (Table 3). Poor baseline
functional status (HAQ) was the only variable associated
with a reduced likelihood of achieving sustained remission
in all analyses (Table 3).
Predictors of sustained LDA
Baseline MTX use, increasing SJC, more recent starting of
anti-TNF and ex-smoker status were associated with
increased likelihoods of sustained LDA for both the
whole cohort and 20012010 subgroup and a greater
PGA was associated with an increased likelihood of sus-
tained LDA for the 20012010 subgroup only.
Adalimumab use was associated with an increased likeli-
hood of sustained remission in the whole cohort, but not in
the subgroups. A greater SJC:tender joint count (TJC)
ratio (i.e. more swollen than tender joints) was associated
with a greater chance of achieving sustained LDA in the
20102013 subgroup only (Table 4).
Higher HAQ, higher ESR, greater BMI and infliximab (vs
etanercept) were all associated with reduced likelihoods
of sustained LDA in all analyses. Increasing TJC, female
gender and greater age at starting anti-TNF treatment
were associated with a reduced likelihood of sustained
LDA for the cohort as a whole and the 20012010 sub-
group (Table 4).
Discussion
This study shows anti-TNF is currently being used in a
significantly different patient population compared with
TABLE 3 Predictors of sustained remission (multivariable model)
Sustained remission
Whole cohort 20012010 subgroup 20102013 subgroup
Variable OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Gender (female) 0.59 (0.53, 0.66) <0.01 0.54 (0.48, 0.60) <0.01 0.78 (0.56, 1.06) 0.11
HAQ (per unit increase) 0.55 (0.51, 0.60) <0.01 0.54 (0.50, 0.60) <0.01 0.57 (0.47, 0.71) <0.01
DAS28-ESR (per unit increase) 0.92 (0.78, 1.07) 0.27 0.81 (0.68, 0.96) 0.02 1.00 (0.68, 1.45) 0.99
BMI (per kg/m2 increase) 0.98 (0.97, 0.99) <0.01 0.98 (0.97, 0.99) <0.01 0.98 (0.96, 1.00) 0.10
SWC:TJC (low, moderate, high) 0.99 (0.87, 1.13) 0.89 0.94 (0.82, 1.08) 0.42 1.26 (0.88, 1.81) 0.21
Disease duration (per year increase) 1.00 (1.00, 1.01) 0.83 1.00 (1.00, 1.01) 0.35 0.99 (0.97, 1.00) 0.12
TJC (per unit increase) 0.98 (0.97, 1.00) 0.08 0.99 (0.97, 1.01) 0.25 0.99 (0.95, 1.03) 0.64
SJC (per unit increase) 1.02 (1.00, 1.03) 0.06 1.03 (1.01, 1.04) <0.01 1.00 (0.95, 1.05) 0.95
PGA (per mm increase) 1.00 (1.00, 1.01) 0.01 1.01 (1.00, 1.01) <0.01 1.00 (0.99, 1.01) 0.45
ESR (per mm increase) 0.99 (0.98, 0.99) <0.01 0.99 (0.99, 0.99) <0.01 0.99 (0.98, 1.00) 0.10
Ex-smoker (vs current) 1.16 (1.02, 1.33) 0.02 1.23 (1.06, 1.41) 0.01 0.91 (0.62, 1.32) 0.61
Never smoker (vs current) 1.10 (0.97, 1.25) 0.14 1.19 (1.04, 1.37) 0.01 0.84 (0.59, 1.22) 0.36
Age at starting biologic
(per year increase)
0.98 (0.98, 0.99) <0.01 0.98 (0.98, 0.98) <0.01 1.00 (0.99, 1.01) 0.79
Infliximab (vs etanercept) 0.66 (0.57, 0.76) <0.01 0.66 (0.57, 0.76) <0.01 0.46 (0.13, 1.60) 0.22
Certolizumab (vs etanercept)   NAa NAa 0.91 (0.65, 1.28) 0.59
Adalimumab (vs etanercept) 1.29 (1.15, 1.46) <0.01 1.18 (1.02, 1.36) 0.02 1.16 (0.78, 1.72) 0.46
Year starting anti-TNF (per year) 1.01 (0.99, 1.03) 0.30 1.05 (1.01, 1.09) 0.01 0.98 (0.81, 1.19) 0.82
Baseline MTX 1.48 (1.33, 1.65) <0.01 1.51 (1.35, 1.70) <0.01 1.14 (0.85, 1.53) 0.37
aCertolizumab was only licenced for RA after 2010.
TABLE 2 Frequency of sustained and point remission and LDA over time
Cohort dataset 20012013 20012010 20102013 P-valuea
Patients, n 14 436 13 115 1321 NA
Sustained remission, n (% of cohort) 2144 (14.9) 1875 (14.3) 285 (21.6) <0.001
Point remission, n (% of cohort) 3175 (22.0) 2802 (21.4) 391 (29.6) <0.001
Sustained LDA, n (% of cohort)
Any sustained LDA (including sustained remission) 3802 (26.3) 3375 (25.7) 427 (32.3) <0.001
Sustained LDA (excluding sustained remission)
(51 episodes point remission everb)
1031 (7.1) 927 (7.1) 106 (8.0) 0.2
Sustained LDA only (no episodes of remission) 627 (4.3) 573 (4.4) 36 (2.7) 0.005
aUnpaired t-test. bIncludes patients who may have one or more recorded occurrences of non-consecutive episodes of
remission.
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when these drugs first became available and much earlier
in the disease course. The mean age at anti-TNF com-
mencement has remained constant, most likely due to
clinicians prescribing the drug in older patients as well
as using it earlier in the disease course. There may also
be a changing disease presentation, with later onset
related to birth cohort effects [13], ageing populations
[14, 15] or changes in environmental factors (e.g. smoking
[16]) that may affect RA onset. Although overall disease
activity and disability is lower at the start of therapy, the
patient perception of the overall disease impact (PGA) has
remained static, suggesting the relationship between dis-
ease activity and PGA may be non-linear. Psychological
and changing health literacy may also play a part, with
more accurate symptom reporting using the PGA in the
recent subgroup [17]. There may also be a ‘floor effect’
among patients enrolled in the BSRBR-RA due to the min-
imum DAS28 score of 5.1 required prior to commencing a
biologic in the UK.
Outcomes have improved over time, with the proportion
of patients achieving either sustained remission or sus-
tained LDA increasing by 7.3% and 6.6%, respectively.
This increase is driven by an increasing proportion of pa-
tients achieving sustained remission, suggesting clinicians
and patients are increasingly successful in targeting re-
mission. Viewed with the data on changing demographics,
disease activity, disability and MTX use by patients, these
results suggest changes in practice over the past decade
are translating into improved outcomes.
The improvements in outcomes over the past 12 years
have been accompanied by a change in associations with
sustained remission and LDA. A major change is the loss
of association between gender and sustained remission/
LDA. Female gender was negatively associated with sus-
tained remission in a systematic review [7] and both sus-
tained remission and LDA analyses for the whole cohort
and 20012010 subgroup analyses (Tables 3 and 4] but
not the 20102013 subgroup. Possible explanations of
this include a relatively small number of men in the
20102013 subgroup, unidentified differential selection
bias or that men and women have become more similar
in reporting RA disease activity. The negative association
between BMI and sustained remission/LDA is in keeping
with other studies in early [18] and established RA patients
taking anti-TNFs [19]. While the statistical significance of
the association between BMI and sustained remission is
lost in the 20102013 subgroup, the direction of the as-
sociation is the same. It is possible that overall increases
in BMI in the 20102013 subgroup compared with the
20012010 subgroup may have blunted the effect of this
relationship.
Although the association between ex-smokers and im-
proved outcomes is in line with existing evidence, no as-
sociation was identified between never and current
smokers. The reason for this is not clear, but may have
been influenced by the use of sustained remission/LDA as
an outcome rather than the EULAR response criteria that
previous studies have used [20, 21]. There may also have
been confounding factors related to smoking that influ-
enced this relationship, particularly as smoking was not
identified as significant in our initial univariable analyses.
Alternatively, it may be that smoking is on the causal path-
way of RA. Supporting this, a study of six cohorts identi-
fied no association between RA disease severity and
TABLE 4 Predictors of sustained LDA
Sustained LDA
Whole cohort 20012010 subgroup 20102013 subgroup
Variable OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Gender (female) 0.65 (0.60, 0.71) <0.01 0.63 (0.58, 0.70) <0.01 0.86 (0.65, 1.15) 0.32
HAQ (per unit increase) 0.61 (0.57, 0.65) <0.01 0.61 (0.56, 0.65) <0.01 0.61 (0.51, 0.73) <0.01
DAS28-ESR (per unit increase) 0.99 (0.86, 1.13) 0.84 0.87 (0.75, 1.01) 0.07 1.18 (0.84, 1.66) 0.33
BMI (per kg/m2 increase) 0.98 (0.97, 0.99) <0.01 0.98 (0.97, 0.99) <0.01 0.98 (0.96, 1.00) 0.02
SJC:TJC (low, moderate, high) 0.97 (0.87, 1.07) 0.50 0.92 (0.82, 1.02) 0.12 1.46 (1.06, 2.02) 0.02
Disease duration (per year increase) 1.00 (1.00, 1.01) 0.23 1.00 (1.00, 1.01) 0.08 0.99 (0.98, 1.01) 0.41
TJC (per unit increase) 0.97 (0.96, 0.99) <0.01 0.98 (0.96, 0.99) 0.01 1.00 (0.96, 1.04) 0.90
SJC (per unit increase) 1.01 (1.00, 1.03) 0.07 1.02 (1.01, 1.04) <0.01 0.98 (0.94, 1.02) 0.38
PGA (per mm increase) 1.00 (1.00, 1.00) 0.21 1.00 (1.00, 1.01) 0.01 1.00 (0.99, 1.01) 0.47
ESR (per mm increase) 0.99 (0.99, 0.99) <0.01 0.99 (0.99, 0.99) <0.01 0.99 (0.98, 1.00) 0.01
Ex-smoker (vs current) 1.15 (1.03, 1.28) 0.01 1.16 (1.04, 1.30) 0.01 1.08 (0.77, 1.51) 0.68
Never smoker (vs current) 1.08 (0.97, 1.20) 0.14 1.11 (0.99, 1.24) 0.08 1.04 (0.75, 1.44) 0.83
Age at starting biologic
(per year increase)
0.99 (0.98, 0.99) <0.01 0.98 (0.98, 0.99) <0.01 1.00 (0.99, 1.01) 0.56
Infliximab (vs etanercept) 0.66 (0.59, 0.73) <0.01 0.66 (0.59, 0.74) <0.01 0.21 (0.06, 0.73) 0.01
Certolizumab (vs etanercept)   NAa NAa 0.80 (0.59, 1.07) 0.14
Adalimumab (vs etanercept) 1.16 (1.05, 1.28) <0.01 1.06 (0.94, 1.19) 0.33 0.89 (0.63, 1.26) 0.51
Year starting anti-TNF 1.02 (1.00, 1.04) 0.05 1.07 (1.04, 1.11) <0.01 1.01 (0.85, 1.19) 0.93
Baseline MTX 1.56 (1.43, 1.70) <0.01 1.57 (1.43, 1.72) <0.01 1.26 (0.98, 1.63) 0.08
aCertolizumab only licenced for RA after 2010.
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smoking when adjusting for ACPA status [22], suggesting
poorer outcomes associated with smoking may be
mediated by ACPA. ACPA status was not included as a
variable in this study, as it has only recently been col-
lected as part of the baseline data in the BSRBR-RA.
The positive association between the SJC and the
SJC:TJC ratio with sustained remission/LDA is in keeping
with existing evidence [23] and suggests increasing SJCs
may be a good clinical predictor of good response to anti-
TNF treatment compared with purely elevated TJCs.
In line with current evidence, MTX prescription at base-
line showed a strong positive association with sustained
remission and LDA. The loss of association between
baseline MTX prescription and sustained remission and
LDA for the 20102013 subgroup could be due to a
number of reasons. The most likely explanation is that
the 20102013 subgroup was insufficiently powered to
identify an association, as the direction of the effect in
the 20102013 subgroup is the same as the overall
cohort and 20012010 subgroup. Alternatively, this
result could be attributed to increasing use of MTX in all
patients, changing demographic profiles, different anti-
TNF agents used in each subgroup (very little infliximab
use in the more recent subgroup), increased anti-TNF
switching (and thus being censored from these data)
and earlier use of anti-TNFs. However, this study did not
investigate switching or length of time on anti-TNF treat-
ment, so it is not possible to quantify this from these data.
It should also be noted that for this analysis, MTX use was
defined as co-prescription at the time of commencement
of an anti-TNF (i.e. baseline entry to the BSRBR-RA), not
at subsequent follow-up visits. Therefore it is possible that
some patients who were co-prescribed MTX at baseline
subsequently stopped taking it and vice versa. Current
evidence suggests combination biologicMTX therapy is
superior to biologic monotherapy [24, 25], although this
evidence is based on ACR and EULAR responses at one
time point rather than sustained remission. This analysis
shows that the benefit of co-prescription of MTX with anti-
TNF in the 20102013 subgroup analysis is less clear and
requires further investigation.
Compared with etanercept, adalimumab had better and
infliximab worse rates of sustained remission and LDA.
Adalimumab may truly be associated with higher rates
of sustained remission and LDA. However, etanercept
and infliximab were first-in-class anti-TNF agents given
to patients with the worst disease activity, greatest dis-
ability and longest disease duration, all factors independ-
ently associated with a lower likelihood of achieving
remission [6, 7] and included in our model. However, a
calendar year effect was identified, suggesting additional
unmeasured factors have changed over time that may
have influenced the results.
In sustained LDA/remission analyses, a greater number
of predictors were identified in the 20012010 subgroup
compared with the 20102013 analysis, which may be
due to different group sizes, although it is possible
increasing treatment standardization has influenced the
latter subgroup results.
This analysis examines one of the most challenging
clinical targets of treatment: sustained remission. Use of
real-world data to examine this endpoint is important, as
clinical trial data are lacking and results from routine clinical
use are often not as favourable as those seen in clinical trial
environments [26]. Furthermore, a clinically pragmatic target
of sustained LDA was evaluated. A comprehensive evi-
dence-based range of clinically useful predictors was se-
lected, making these results applicable to clinical settings.
This study has limitations. It is an observational study
and, as such, causality cannot be demonstrated. Although
recruitment to the BSRBR-RA is nationwide and has
broad inclusion criteria, there may be unidentified selec-
tion biases. There is real-world variation in follow-up pat-
terns that result in variable sequential follow-up data and
there are different recruitment windows that may have
influenced results (see Supplementary Table S1, available
at Rheumatology online). Remission was defined accord-
ing to DAS28 criteria, which is known to be more lenient
than contemporary definitions [27, 28]. The lack of a phys-
ician global assessment of disease activity in routine
BSRBR-RA data collection precluded analysis of newer
composite outcome measures. We have used an evi-
dence-based approach to select the predictors to use in
the regression models and other co-morbidities, autoan-
tibodies and radiographic endpoints were not identified as
predictors of sustained remission in the previous system-
atic review [7], so these were not included in this analysis.
Furthermore, ACPA status was not included in data col-
lection from registry inception and radiographic outcomes
are not collected by the BSRBR-RA.
The sample size of the two subgroups was different,
which may have reduced the likelihood of observing as-
sociations within the 20102013 subgroup. However, this
subgroup still included >1300 patients, which was larger
than most of the studies identified in our systematic
review [7]. We did not stratify analysis by anti-TNF drug,
and it is possible that there are variations in predictors of
remission/LDA between anti-TNF agents that may have
influenced our results (including smoking and MTX).
However, further subgroup analysis by anti-TNF drug
would have led to small group sizes that would have
been underpowered. This analysis did not include data
on concomitant DMARDs other than MTX. NSAID or ster-
oid use variables were not included, as the granularity of
these data were not sufficient.
Conclusions
Despite improvement in outcomes, it is sobering to note
that between 68% and 78% of patients do not achieve
either sustained LDA or remission.
This study highlights the importance of modifiable fac-
tors (reducing BMI and smoking cessation) and is in line
with most current standard public health advice. It also
shows that clinically demonstrable evidence of inflamma-
tion (swollen joints) are a good predictor of future sus-
tained response and supports the paradigm of
aggressive treat-to-target clinical practice. Conversely
however, it also suggests individuals with high TJCs in
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the absence of clinical inflammation are less likely to ex-
perience resolution of symptoms and is in keeping with
findings from a recent Norwegian DMARD study [29].
The finding that MTX does not increase the likelihood of
achieving sustained remission or LDA in the most recent
subgroup requires further investigation before any
changes to guidance can be issued.
These results challenge assumptions about the treat-
ment of RA patients with anti-TNF and show that patients
treated in clinical practice today and the associations with
sustained remission and LDA are significantly different
from when anti-TNF first became available.
Additional work is required to examine if predictors iden-
tified in this study are generic to all biologic-class drugs or
if nuances are observed between different biologic classes
that could help tailor treatment to individual patients.
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